摘要
Dear Editor,In combination,anti-CTLA-4 and anti-PD-1 mAb provide the most effective immunotherapy,although severe immune-related adverse events(irAEs)also occur at high frequency.1 It is urgent to develop strategies to reduce irAEs for wide-spread adoption of immune checkpoint inhibitors(ICIs).
基金
supported by a Team Science Award 559400 from Melanoma Research Alliance(P.Z.,S.H.,and Y.L.)
NIH grant R01CA227671(P.Z.)
R01AI154722(X.W.,X.D.,Y.Z.,Y.L.,and P.Z.)
OncoC4(M.L.,Y.L.,and P.Z.)。
